Page 20 - Pharmaceutical Firms

Fewer Indian pharma plants get US FDA action notice in 2023, so far

6 per cent of inspections in first 6 months of CY23 resulted in OAI status

2 more Indian drugmakers under lens in Nigeria for 'contamination'

Nigerian health agency flags off paracetamol, cough syrup

10,000 Jan Aushadhi Kendras expected to be functional by year-end: Official

Applications have been invited for setting up more Jan Aushadhi Kendras as around 10,000 such centres are expected to be made functional by the year-end, a top official said on Friday. Ravi Dadhich, CEO of Pharmaceuticals and Medical Devices Bureau of India (PMBI) said, "10,000 Jan Aushadhi Kendras are expected to be functional across the country by the end of the year." He added that applications have been invited for the proposals to establish these centres. As on May 31, a total of 9,484 Jan Aushadhi Kendras are operational in the country. Dadhich made the comments in an interaction with media persons assembled at the central warehouse, Bilaspur, Gurugram. There are currently four warehouses in the country under Pradhan Mantri Bharatiya Jan Aushadhi Pariyojana (PMBJP), located at Gurugram (Haryana), Chennai, Guwahati and Surat, with the central warehouse at Gurugram being the largest. At present, PMBJP is providing 1,800 medicines, as well as 285 surgical devices at highly ...

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Majority of analysts positive on the stock; their average target price indicates an upside potential of 15 per cent

Gambia death fallout: Pharma exports to African market slipped 5% in FY23

Medicines put up for retail sales led the decline in exports

Janus Henderson further downgrades PharmEasy valuation to $ 2.7 billion

Several other Indian startups such as Meesho, Swiggy, Byju's, Pine Labs, and Ola have seen similar cuts in their valuations

Medical devices must display essential information on packaging: Govt

The department of consumer affairs has mandated that pharmaceutical clearly display important information on their packaging so consumer can make informed decisions

JB Pharma Q4 PAT rises 3.5% to Rs 88 cr, revenue stands at Rs 762 cr

JB Pharma on Wednesday said its profit after tax rose by 3.5 per cent to Rs 88 crore for the fourth quarter ended March 31, 2023. The company had reported a profit after tax (PAT) at Rs 85 crore in the January-March quarter of 2021-22 fiscal. Revenue of the company stood at Rs 762 crore in the fourth quarter of FY23 as against Rs 625 crore in the same period of FY22, JB Pharma said in a statement. For the last fiscal, the company reported revenue of Rs 3,149 crore as compared with Rs 2,424 crore in FY22. During the same period, PAT stood at Rs 410 crore as against Rs 386 crore, recording a growth of 6 per cent, JB Pharma said. The drug maker continued its growth journey in the fourth quarter, thereby ending FY23 with a strong performance across business segments, JB Pharma CEO Nikhil Chopra said. "While we are cautious of the inflationary environment our efforts are aimed at executing well, with productivity and cost optimisation as drivers, in order to deliver improved operating

Pharma companies seek price ceiling exemption for low-cost medicines

The industry and the government are on the same page on trade margin rationalisation, however, the industry wants it to be implemented in a phased manner

Janus Henderson marks down PharmEasy's valuation by half to $2.8 bn

Neuberger Berman, another US investor, earlier marked down valuation of shares it holds in online pharmacy's parent

Dr Reddy's Labs Q4 result: PAT up 9 times, div declared at Rs 40 per share

Its revenue from operations stood at Rs 5,843 crore in Q4 FY23, up 15.28% YoY as compared to Rs 5,068.4 crore in Q4FY22

NPPA to cap medicine prices to boost affordability, curb profiteering

The change could have financial implications for leading drug manufacturers like Abbott Laboratories, Bayer AG, and GlaxoSmithKline, among others

JB Chemicals & Pharmaceuticals to consider sub-division of equity shares

A final decision on this will be taken during the board meeting to be held on 24 May 2023

Lupin to acquire French pharma company Medisol for around Rs 160 crore

The company has entered into a definitive agreement to acquire the entire share capital of Medisol, subject to approval from the French Ministry of Economy and Finance

Govt pays PLI incentives worth Rs 2,874 crore towards 8 sectors in FY23

Empowered group of secretaries, Aayog review some sectors to bring them to 'acceptable levels'

Serum Institute to double its investment in Biocon's unit to $300 million

SILS will now make an additional equity investment of $150 million through the conversion of an earlier loan provided to Biocon Pharma into equity in BBL

India business to boost pharma, after US sales prove to be a mixed bag

Hospitals to recover from sluggish Q3; diagnostics growth rate at pre-Covid levels

Big pharma: Here's why India's drug industry needs a major overhaul

The latest drug recalls just add to a long line of scandals that have tainted the pharma sector of India

Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 observations and adverse outcomes

Natco launches additional strengths of generic version of Revlimid in US

Natco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, in the US. The company has launched 2.5 mg, and 20 mg strengths of the generic version of Revlimid (lenalidomide capsules) through its marketing partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, Natco Pharma said in a regulatory filing. "With this launch the companies (have) made available all the strengths of lenalidomide in the US market," it added. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma, the filing said.